Resignations of Senior Executives Follows China’s Biggest Financial Fraud Trial

Investors look at computer screens showing stock information at a brokerage house in Shanghai, China, April 21, 2016. Aly Song/Reuters

Analysis

Numerous independent directors of companies listed on the Shanghai and Shenzhen stock exchanges have resigned after the conclusion of the Kangmei Pharmaceutical trial, which found the health care company guilty of fabricating its financial statements.